PDS Biotechnology Announces Treatment of First Patient with PDS0101 based on the Novel Versamune™ Cancer Immunotherapy Platform in a Phase 1 Clinical Trial

  • PDS Biotechnology Announces Treatment of First Patient with PDS0101 based on the Novel Versamune™ Cancer Immunotherapy Platform in a Phase 1 Clinical Trial

    February 11, 2014, North Brunswick, NJ – PDS Biotechnology Corp., a clinical-stage biotechnology company focused on the development of novel immunotherapy treatments for cancer and other chronic diseases, as well as novel preventive vaccines, today announced that the first patient has been successfully vaccinated with PDS0101 in a Phase 1 clinical trial in patients with cervical intraepithelial neoplasia.

    The trial which is being conducted at three leading gynecological oncology centers in the United States is designed to evaluate the safety, feasibility and immunological responses of the novel Versamune™-based PDS0101 cancer immunotherapy in patients with cervical intraepithelial neoplasia.

    “The ability to effectively train and prime our body’s immune system to specifically target and kill cancer cells has recently shown significant promise in treating various cancers” said Dr. Frank Bedu-Addo, CEO of PDS Biotechnology. “Should the unique safety profile and efficacy of Versamune™ and PDS0101 demonstrated in preclinical studies be successfully replicated in humans, this will represent a significant advancement in the treatment of cancer. It would also represent a significant advancement in the treatment of early-stage cancer and certain infectious diseases where there is a high and growing unmet medical need not addressed by current approaches.”

    PDS-Biotech

    Comments are closed.